GDS Wealth Management Has $13.79 Million Holdings in IQVIA Holdings Inc. $IQV

GDS Wealth Management raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 31.6% during the 2nd quarter, HoldingsChannel reports. The fund owned 87,491 shares of the medical research company’s stock after purchasing an additional 21,020 shares during the period. GDS Wealth Management’s holdings in IQVIA were worth $13,788,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Everpar Advisors LLC raised its stake in shares of IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 62 shares in the last quarter. Private Trust Co. NA grew its stake in IQVIA by 12.5% in the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after buying an additional 67 shares during the last quarter. Independent Advisor Alliance raised its holdings in IQVIA by 4.2% in the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock worth $318,000 after acquiring an additional 72 shares during the period. Nemes Rush Group LLC lifted its position in IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock worth $109,000 after acquiring an additional 81 shares during the last quarter. Finally, Penserra Capital Management LLC increased its stake in shares of IQVIA by 10.3% in the second quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock worth $151,000 after purchasing an additional 90 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research analyst reports. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Evercore ISI raised their price objective on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. Baird R W raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. Jefferies Financial Group upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Finally, BMO Capital Markets assumed coverage on IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $240.61.

IQVIA Trading Up 0.1%

Shares of IQVIA stock opened at $217.50 on Thursday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $228.12. The stock has a market capitalization of $37.04 billion, a P/E ratio of 29.84, a price-to-earnings-growth ratio of 2.44 and a beta of 1.34. The company has a 50-day simple moving average of $204.51 and a 200 day simple moving average of $180.05. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same period in the prior year, the firm earned $2.84 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.